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Abstract
Background: Complex Regional Pain Syndrome (CRPS) is a disabling disease that is sometimes difficult to treat.
Although spinal cord stimulation (SCS) can reduce pain in most patients with CRPS, some do not achieve the desired
reduction in pain. Moreover, the pain reduction can diminish over time even after an initially successful period of SCS.
Pain reduction can be regained by increasing the SCS frequency, but this has not been investigated in a prospective
trial. This study compares pain reduction using five SCS frequencies (standard 40 Hz, 500 Hz, 1200 Hz, burst and
placebo stimulation) in patients with CRPS to determine which of the modalities is most effective.
Design: All patients with a confirmed CRPS diagnosis that have unsuccessfully tried all other therapies and are eligible
for SCS, can enroll in this trial (primary implantation group). CRPS patients that already receive SCS therapy, or those
previously treated with SCS but with loss of therapeutic effect over time, can also participate (re-implantation group).
Once all inclusion criteria are met and written informed consent obtained, patients will undergo a baseline assessment
(T0). A 2-week trial with SCS is performed and, if successful, a rechargeable internal pulse generator (IPG) is implanted.
For the following 3 months the patient will have standard 40 Hz stimulation therapy before a follow-up assessment
(T1) is performed. Those who have completed the T1 assessment will enroll in a 10-week crossover period in
which the five SCS frequencies are tested in five periods, each frequency lasting for 2 weeks. At the end of the
crossover period, the patient will choose which frequency is to be used for stimulation for an additional
3 months, until the T2 assessment.
Discussion: Currently no trials are available that systematically investigate the importance of variation in
frequency during SCS in patients with CRPS. Data from this trial will provide better insight as to whether SCS
with a higher frequency, or with burst stimulation, results in more effective pain relief.
Trial registration: Current Controlled Trials ISRCTN36655259
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Background
Complex Regional Pain Syndrome (CRPS) is defined as a
collection of locally appearing painful conditions follow-
ing a trauma, which mainly occurs distally and exceeds
in severity and duration the expected clinical course of
the original trauma; this often results in considerably re-
stricted motor function and is characterised by a variable
progression over time [1]. The diagnosis of CRPS in the
acute phase is made with the aid of the new criteria of
the International Association for the Study of Pain
(IASP). These criteria have a high sensitivity of 0.99 and
a much improved specificity of 0.79 compared with the
previously used diagnostic criteria, such as the Veldman
criteria and the Orlando criteria [2–4].
The natural course of the disease is not always
favourable, even with a multidisciplinary approach and the
use of evidence-based guideline-supported treatment algo-
rithms. CRPS has an estimated incidence of 5.46–26.2 per
100,000 person years (95 % CI: 23.0–29.7) [5, 6] and a
prevalence of 20.57 per 100,00. Women are affected more
frequently than men (with a ratio of 3.4–4.0:1) and CRPS
occurs more often in the upper extremities [5, 6]. The
main initiating cause is a fracture, but other traumatic or
spontaneous onsets are well documented [3, 5].
Although the pathophysiology of CRPS is incom-
pletely understood, several mechanisms are proposed
to contribute to this disease such as inflammation,
vasomotor dysfunction, and involvement of the central
nervous system with features of central sensitisation
and neuroplasticity [7].
Some patients with diagnosed CRPS are unresponsive
to any conventional therapy, such as physical therapy,
medication and invasive interventions such as sympa-
thetic blockade. In these cases there is a clear indication
for spinal cord stimulation (SCS) as a last resort therapy
to reduce pain. SCS has been performed in many CRPS
patients and has shown an evident and clinically relevant
pain reduction that can be maintained for a prolonged
period of time [8–12].
The exact mechanism of action that occurs during SCS,
which results in pain relief, has not been fully elucidated.
However, it is known that for neuropathic pain in general,
SCS decreases the hyperexcitability of the multimodal
wide dynamic range neurons (WDR), increases the release
of gamma-aminobutyric acid (GABA) in the dorsal horn
and, subsequently, decreases the release of glutamate.
Other mechanisms proposed to be involved are activation
of an inhibitory descending pathway and involvement of
the cholinergic system. Several CRPS-specific mecha-
nisms of SCS are considered to play a pivotal role,
such as inhibiting the hyperexcitable central neural cir-
cuitry, a decrease in the efferent-sympathetic output
and by antidromic activation which, in turn, causes the
release of several vasoactive substances, such as nitric
oxide, substance P and calcitonin gene-related peptide
[13–15].
However, despite these successes some CRPS patients
are not responsive or, in others, the pain-reducing effect
diminishes over time due to tolerance [9–12]. It is sug-
gested that pain relief in some of these tolerant non-
responsive patients can be recaptured by increasing the
SCS frequency to 250 Hz and beyond [16]. Also, burst
SCS is a novel stimulation modality that can reduce
pain, but has not yet been investigated in patients with
CRPS [17, 18]. Further research is needed to gain more
insight into the (patho)physiological mechanisms of
CRPS and to elucidate the effects of SCS when stimulat-
ing with different frequencies and waveforms.
Aim
This study aims to compare the effects of five different
SCS modalities in patients with CRPS and determine
which frequency is most effective in terms of pain reduc-
tion; these frequencies are standard stimulation with
40 Hz , 500 Hz, 1200 Hz, burst and placebo stimulation.
Methods
Study design
This is a prospective randomised, double-blind and
placebo-controlled crossover trial. The study is a multi-
centre trial including one university hospital and four
regional hospitals located throughout the Netherlands.
Figure 1 provides an overview of the study and Fig. 2 a
detailed overview of the crossover trial.
Study population
Patients considered for enrollment in this trial must be
diagnosed with CRPS that is in accordance with the
endorsed IASP criteria at the time of disease onset. We
defined two groups of patients that can take part in this
trial. The first group (primary implantation group) con-
sists of patients with chronic CRPS who are unresponsive
to conventional therapies (e.g. pharmacologic treatment,
interventional blockade of the sympathetic nervous sys-
tem, or physical therapy aimed at increasing or regaining
functionality by training programs). The second group (re-
implantation group) consists of patients who already have
SCS therapy, or were treated with SCS in the past but with
loss of therapeutic effect over time. In the re-implantation
group it is imperative that the paresthesia, that is or was
felt under SCS therapy, has adequate overlap with the
painful area.
Inclusion and exclusion criteria
Eligibility for SCS is in accordance with the Dutch CRPS
and Neuromodulation Guidelines. These guidelines state
that patients must have a mean pain intensity of a least
5, as measured on a visual analogue scale (VAS; range
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Fig. 1 Flowchart of the entire study
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0–10), a CRPS duration of at least 12 months, and no
lasting success or complications with conventional ther-
apy. An additional requirement for this study is that the
CRPS is located in one extremity only. Exclusion criteria
are: anticoagulant drug therapy or disturbed coagula-
tion, age < 18 years, pregnancy, ICD or pacemaker, life
expectancy < 1 year, lack of cooperation of the patient,
drugs, medication or alcohol addiction, and immune-
compromised patients.
Ethical approval
Approval from the Medical Ethics Committee of Erasmus
Medical Center Rotterdam was obtained in August 2011
(Registration number: MEC-201 1-012). The trial was sub-
sequently registered in the Current Controlled Trials
register (ISRCTN 36655259). Written informed consent is
obtained from all patients before enrollment into the trial.
Primary outcome parameters
The main study parameters are pain reduction and patient
satisfaction. The pain scores are measured with the McGill
Pain Questionnaire-Dutch Language Version (MPQ-DLV)
[1, 19] and a 4-day VAS diary measurement is used to
monitor pain intensity during the morning, afternoon and
evening. The Global Perceived Effect (GPE) is measured
by two questions on a 7-point Likert scale [9]. The VAS
score is considered the main primary outcome param-
eter out of these three. All questionnaires are com-
pleted by the patient.
Secondary outcome parameters
Secondary outcomes consist of detecting temperature
asymmetry by using video thermography imaging [20–27],
and electrical quantitative sensory testing (e-QST)
together with the conditioned pain modulation (CPM)
[28–32]. Current Perception Threshold (CPT), Pain Per-
ception Threshold (PPT) and Pain Tolerance Threshold
(PTT) are measured with e-QST and provide more insight
into the disease characteristics, such as hyperalgesia,
hypoalgesia and allodynia. The CPM paradigm will pro-
vide further details on the patient’s pain suppression
system.
A MicroFet Dynamometer® is used to measure muscle
strength of the flexors and extensors of the elbow in case
of the upper extremity, and of the knee and the foot in
case of CRPS in the lower extremity. The grip strength
and the pinch strength is determined by means of a
Jamar Hydraulic Hand Dynamometer® and a Jamar
Hydraulic Pinch Gauge®, respectively. The pinch strength
is measured in two ways: thumb tip to index fingertip,
and thumb pad to lateral aspect of middle phalanx of
index finger; the biceps and the triceps. In addition, a
walking test is performed only in patients that have
























Fig. 2 Detailed flowchart of the crossover period
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takes to cover a 10 m distance when walking at a com-
fortable and maximum walking pace. Furthermore, the
maximum walking distance is assessed during a 2-min
walk where the patient is instructed to cover as much
distance as possible within these 2 min [33–40].
The types of activity and physical activity level (PAL)
of a patient is continuously measured with the VitaMove
system (2 M Engineering, The Netherlands) for multiple
days (2–3 day), providing a detailed and continuous
report on the patient’s energy expenditure, motions and
postures over the course of several days [41–46]. This
device is capable of interpreting various positions like
sitting, standing and lying down as well as discerning
various activities like walking, running, cycling or gen-
eral motion of the arms, legs and trunk. The PAL can be
estimated with the VitaScore software that calculates the
energy expenditure with the aforementioned activities
and the patients characteristics like weight, height, age
and sex to estimate the basal metabolism. The energy
expenditure can provide information on the level of
activity of a patient that ranges from extremely inactive-
extremely active.
Artificial skin blisters are created to measure whether
local inflammation is still present in these patients
before SCS and the effects stimulation therapy might
elicit on the inflammatory profile [47–56]. A blood test
is performed to assess the outcome of the endogenous
opioids (such as dynorphin, endorphin and encephalin)
before and after SCS [57–59]. An additional consent
must be signed by the patient in order to perform both
the blood and artificial skin blisters test.
Multiple questionnaires are filled in by the patient
throughout the course of the study to monitor the various
dimensions (Table 1). These include psychological and so-
cial evaluation: Inventory for Social Support (ISS) [60],
Pain Catastrophizing Scale Dutch Version (PCS-DV) [61–
63], RAND-36 [64–66], the Hospital Anxiety and Depres-
sion Scale (HADS) [67, 68] and the Tampa Scale for Kine-
siophobia (TSK) [69, 70]. Physical activity: the Disabilities
of Arm Shoulder and Hand Questionnaire (DASH) [42,
71, 72] when the upper extremity is affected, and the
Walking Ability Questionnaire when the lower extrem-
ity is affected [73–75]. Economic evaluations: The cost
analysis is performed from a societal viewpoint in col-
laboration with the Institute for Medical Technology
Assessment of Erasmus University Rotterdam. Three
categories of costs are distinguished: 1) Direct costs
within the healthcare system, 2) Direct costs outside
the healthcare system, and 3) indirect costs outside the
healthcare system. These data are collected using diar-
ies and the Trimbos/iMTA questionnaire for Costs as-
sociated with Psychiatric Illness (TiC-p) and health
consumption, simultaneously with the clinical data and
quality of life data. The costs are valued using the
Dutch guidelines for cost analysis in healthcare (Health
Care Insurance Board).
Productivity costs: The productivity costs are defined as
the costs of absence from paid work due to CRPS, includ-
ing the impact of compensation mechanisms, the cost of
efficiency losses (productivity costs while working at a
slower pace) and the costs of hindrance at unpaid work.
For this, the three modules of the PRODISQ questionnaire
for measuring and valuing productivity costs for unpaid
work are used [76, 77]. For costs related to unpaid work
we use a module of the Health and Labour Questionnaire
(HLQ) [78]. For the valuation of productivity losses, the
friction cost method is used, taking into account that in a
production process everyone is replaceable after a certain
period (the so-called friction period). For the valuation of
each hour of productivity lost (and the length of the fric-
tion period) we use the guidelines as presented in the cost-
ing manual [79].
Medication consumption is assessed by taking an
inventory of all (pain)medication and dosing the patients
use at the time of the T0, T1 and T1 assessment. The
pain medication will be stratified into the various medi-
cation groups and a the sum dosage of the various pain
medication groups will be calculated.
Sample size calculation
By means of MANOVA for repeated measurements
within factors, the potential differences in effect of the
five different stimulation modalities will be assessed. A
minimal detectable effect size (f ) of 0.15 on the main
primary outcome parameter pain intensity (VAS) was
chosen. The required minimum number of participating
patients is negatively associated with the correlation
between measurements during the cross-over. Unfortu-
nately, no data of previous research on this correlation
were available at the time of setting up this study. There-
fore, we made an conservative guess and a correlation of
0.6 was chosen. Thus, assuming a power of 0.8 and a
significance level (σ) of 0.05 , an a priori sample size of
48 is required.
Randomisation and blinding
Randomization was performed with a computer based
program at the beginning of the trial and no blocks were
used since this is not viable in our study design. In our
study design all patients in the crossover will be subjected
to all five stimulation modalities in random order, result-
ing in 5! (120) different orders in which the stimulation
modalities can be programmed. Only 48 (the required
sample size) of these 120 potential different orders are
selected at random by the computer to be used.
The specific order of the programming for an individ-
ual patient is revealed to the local SCS programmer only
during each of the five crossover periods. The patient is
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blinded for the intervention by means of a mask that
cannot be seen through. The outcome assessments at
the end of each 2-week period are done by means of
questionnaires. The statistician who performs the ana-
lysis of the measurements and questionnaires is blinded
for the allocation key for the treatments for each patient.
Statistical analysis
Data are analyzed using the latest version of IBM SPSS
Statistics. Descriptive statistics are used to determine the
frequencies of the demographic and secondary outcome
parameters, and to describe measures of central ten-
dency and of dispersion, dependent on the shape of their
distribution. The Kolmogorov-Smirnov test is used to
analyze whether or not the scores on the these parame-
ters are normally distributed. The outcome parameters
are analyzed using Mixed Linear Models for repeated
measurements within factors model. These Mixed Linear
Models model require normality of residuals. These
models are however relatively robust against violations
of this assumption [80]. Therefore, the results are pre-
sented as mean ± the standard deviation (SD). Further-
more, a Bonferroni test will be performed in the
pairwise comparison of the modes of stimulation only if
the result of the overall analysis results in the rejection
of the H0-hypothesis of no significant differences be-
tween the modes of stimulation. Therefore, to test this
H0-hypothesis we will use the traditional rejection zone
of 5 %. The primary analysis will not make a distinction
between primary implantation group vs. re-implantation
group since the vast majority of the included patients
will be SCS naïve. This matter should than be dealt with
in a post hoc testing.
Pre-trial assessment
Patients with an indication for neuromodulation are
referred by their physicians to the SCS nurses for
further evaluation, and to provide them with additional
information about the procedure and lifestyle limita-
tions. Also, a psychologist will screen the patient to rule
out any psychological contraindication that might influ-
ence the outcome of the SCS trial. The patients are con-
tacted by the researcher for trial information and
enrollment once all the clinical inclusion criteria for SCS
treatment have been met. After obtaining written ob-
tained consent from the patient, the next phase in the
trial can commence. It is noteworthy that patients who
Table 1 Data collection overview throughout the entire study
T0 T1 C1 C2 C3 C4 C5 C6 T2
Medical History x
Physical examination x x x
Stimulation evaluation x x x x x x x
Pain diary x x x x x x x x
McGill Pain Questionnaire x x x x x x x x
Global Perceived Effect x x x x x x x
Final assessment frequency chosen x
HADS x x x
RAND-36 / SF-36 x x x
PCS x x x
ISS x x x
TSK x x x
DASH x x x
Walking Ability Questionnaire x x x
Prodisq A-E x x x
TiC-p and Healthcare consumption x x x
Thermographic imaging x x x
Muscle strength x x x
Walking Test (if applicable) x x x
QST x x x
CPM x x x
Blood and Blister test (optional) x x x
Physical activity monitoring x x x
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decline to participate in the trial will still be treated with
regular SCS therapy.
Baseline measurement T0
The patient is invited to our medical centre to partici-
pate in various test that are conducted as well as medical
history and physical examination. All questionnaires
must be filled in by the patient prior to this visit. Table 1
presents an overview of the tests and measurements that
are performed during the entire course of this trial. The
results of the T0 tests will serve as a baseline and all
subsequent evaluations will be compared with these re-
sults. An additional requirement for the patients that
still have an active SCS device is to switch off the stimu-
lation for at least 1 week before T0. This will provide ob-
jective insight into the disease characteristics and pain
that would otherwise be masked by the SCS therapy.
Figure 1 presents a complete overview of the various
phases in this trial.
Trial stimulation and implantation
The trial stimulation is conducted at the various hospitals
attended by the patients and lasts for 2 weeks. Only expe-
rienced physicians are allowed to perform implantation.
During the test stimulation the patient is positioned in the
prone position and spinal column landmarks are identified
with fluoroscopy. Local anaesthetics are used during this
procedure; however, a mild sedative or short-acting opi-
oid can be used without compromising the patient’s
ability to cooperate during the intra-operative testing.
The surgical procedure used is left to the discretion of
the physician in charge.
The cylindrical percutaneous Octrode™ lead (St. Jude
Medical, Plano, TX, USA ) is primarily used in all patients
to gain unilateral stimulation and is positioned under
fluoroscopic guidance. The correct position is determined
by means of intra-operative stimulation and is deemed
successful if the induced paresthesia has an adequate over-
lap with the painful area. The lead is sutured to the fascia
using an anchor. An extension cable is attached to the lead
and is tunneled under the skin towards a suitable exit site.
A temporary battery is attached to the external part of this
extension cable during the trial period.
The parameters used for stimulation is up to the SCS
nurse in charge, except for the mandatory frequency set-
ting of 40 Hz. All other parameters (such as electrode
configuration, pulse width and current output levels) are
the result of the individual clinical paresthesia mapping.
The trial period will generally last for 1 or 2 weeks and
is considered successful if a patient has >50 % pain
reduction on a VAS and/or has stated that the symptoms
are much improved. All patients with a successful trial re-
ceive a permanent rechargeable internal pulse generator
(IPG) from the Eon family line (St. Jude Medical, Plano,
TX, USA) under general anaesthesia. The trial extension
cable is removed and replaced with a new extension cable
that is connected to the IPG. In some instances, a direct
connection with the lead and IPG can be made if the
length of the lead is sufficient. The pocket location for the
IPG is free of choice and can either be in the lower abdo-
men or in the gluteal are. All materials are removed if a
trial is unsuccessful and the patient is then excluded from
further follow-up during this trial. The standard stimula-
tion setting is further optimised during the regular
checkups in the subsequent weeks. Antibiotic prophylaxis
is given during both the trial and implantation in accord-
ance with the local hospital antimicrobial guidelines.
Follow-up measurement T1
Three months after the IPG implantation and therapy
with normal tonic 40 Hz SCS, another assessment (T1)
takes place. This serves as an evaluation of the effects of
regular SCS on the previously described tests (Table 1).
Enrollment into the crossover part of this trial can only
commence after completion of this phase.
Crossover
The crossover period consists of five periods (each lasting
for 2 weeks) in which the 5 different frequencies are
tested. After each period, a small assessment (S1-S5) is
done to evaluate the stimulation effects on pain and GPE.
A 2-day wash-out period, during which the stimulation is
switched off, is incorporated at the beginning of the first
2-week period (S1) and at the end of each period. The
purpose of a wash-out period is to objectively determine
the baseline pain levels and symptoms of CRPS when they
are not masked by SCS, and to minimise the carryover
effects of the previous period into the next period. The
small assessments (S1-S5) comprise a stimulation evalu-
ation, a pain diary, the McGill Pain Questionnaire and the
Global Perceived Effect. Stimulation evaluation requires a
patient to keep a stimulation diary in which they must
answers four questions; (1) the effect(s) of stimulation on
pain in the CRPS effected area, (2) if they feel paresthesia
and if so where do they feel it and how is the stimulation
described, (3) how they would rate the ease of use of the
stimulation, (4) the advantages and (5) the disadvantages
per stimulation modality. A detailed overview of the cross-
over period is provided in Fig. 2.
During the final evaluation (S6) a decision is made by
the patient regarding which stimulation modality is to
be used for the subsequent 3 months at the end of these
5 periods. This decision is mainly based on pain reduc-
tion, but also on other CRPS-related symptoms and
practical matters related to the stimulation. The patient
continues with their stimulation of choice for another
3 months. A switch of stimulation within these 3 months
is possible in certain cases.
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Programming the various frequencies
The five stimulation modalities are all programmed in
such a way the maximum effect pain be obtained.
Standard 40 Hz stimulation will be performed above
threshold which generates paresthesia in the affected
area and is in accordance with normal practice. Both
500 Hz and 1200 Hz will be above threshold stimula-
tion and will also generate paresthesia. At the time this
study protocol was postulated there were no other re-
ports available on how best to program 500 and
1200 Hz SCS based on mechanisms of action. Thus, in
absence of evidence stating the contrary, we decided to
program 500 and 1200 Hz SCS like standard 40 Hz
stimulation with the intention to induce paresthesia
and thus being an above threshold stimulation. Placebo
stimulation is performed with the IPG switched off and
thus does not generate paresthesia. The rationale is to
evaluate how big a part of the pain relief could be
attributed to the placebo effect. Burst stimulation is
performed with fixed stimulation parameters and the
intensity of the stimulation will be sub-threshold and
therefore is does not generate paresthesia. The fixed pa-
rameters of burst stimulation are: an overall frequency of
40 Hz per burst complex. Each burst complex delivers 5
spikes with a frequency of 500 Hz and a pulse width per
spike of 1 ms and an inter-spike interval of 1 ms. The
charge is balanced during the 15 ms pause between the
burst complexes.
Follow-up measurement T2
The T2 assessment is performed when a patient has
completed the 3-month period with the frequency of
choice. This T2 evaluation enables us to compare all the
primary and secondary outcomes parameters with the
T1 assessment with standard SCS and the baseline T0
assessment prior to SCS therapy. The patient is actively
asked whether they want to continue with the SCS pro-
gram they have chosen, or want to switch to another
one based on the crossover results.
Trial completion
After completion of this trial the patient will continue
with the chosen stimulation and a clinical follow-up is
performed once a year by the physicians and nurses.
Discussion
Data obtained from this trial will provide better insight
as to whether SCS, as it is currently applied, is the best
available therapy modality, or whether stimulation with
a higher frequency or with burst stimulation results in
better pain relief. Another result might be that these
new modalities of stimulation are equally preferred by
the patients. Irrespective of the outcomes, this trial will
provide new insights into the mechanisms of action
involved in SCS treatment and, particularly, in patients
with CRPS.
For this trial, standard SCS was defined as stimulation
with 40 Hz and corresponds with the normal stimulation
setting used in our daily practice. The choice to select
500 Hz was based on studies reporting that blood flow
and endogenous opioid release are at their maximum
while applying SCS at this frequency [57, 59, 81]. The
1200 Hz stimulation was chosen because it is the max-
imum that can be generated with this IPG. Burst stimula-
tion was selected because the stimulation differs
significantly from tonic stimulation in terms of waveform
and working mechanism. It is reported that burst SCS can
effectively reduce pain in patients with neuropathic pain
[17, 18, 82–84].
High-frequency SCS (HF-SCS) with 10,000 Hz is also
available and multiple studies have shown its effect in pain
patients and its ability to reduce pain over a longer period
of time [85, 86]. Our 1.2 kHz stimulation does not
approach the 10 kHz used in the latter studies, but no
clinical studies are available that compare these frequen-
cies. However, some animal studies have compared the
effects of normal frequency SCS with different HF-SCS
settings. Song et. al. compared conventional suprathres-
hold stimulation of 50 Hz with that of subthreshold HF-
SCS at 500 Hz, 1 kHz and 10 kHz and concluded that the
hypersensitivity after nerve lesions was reduced in all the
HF-SCS groups and that the reduction was equal to that
of the normal SCS group [87].
Burst stimulation is a new concept which requires a
totally different programming algorithm in daily practice.
The stimulation must be programmed to a sub-threshold
current output level so that a patient will not experience
paresthesia. This paresthesia free ‘side-effect’ can be used
to incorporate a placebo element into the trial where
paresthesia cannot be felt because the stimulation is
switched off.
The question remains if a 2 week test period per fre-
quency along with a 2 day wash-out to counteract the
possible carryover effects of the various frequencies are
enough. In clinical practice a patient can conclude
whether the SCS is beneficial to him/her within a two
week period during trial SCS. We choose to maintain
the 2 week per period analogy in the crossover period
which should provide the patient with enough time to
decide if one of the test frequencies is beneficial or not.
Moreover, by increasing the crossover period to 3 weeks
or even longer the possibility of patient withdrawal from
the study increases in case one of the test stimulations
does not provide (sufficient) pain relief. This is further
supported by what clinicians hear from patients that the
pain returns when the stimulation is switched off. Some
experience an instantaneous increase in pain while
others report that it takes a few minutes or a few hours
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before the pain has fully returned, but never longer than
24 h. On these arguments we decided on a wash-out
period of 2 days between the various stimulation modal-
ities to be tested [88–90].
A potential pitfall in the design of the present trial that
might influence the patient’s choice, is that the patients
are preconditioned with standard stimulation for the
first 3 months. On the other hand, if they do choose a
SCS setting other than the standard one, it is a choice
they make despite the odds being in favour of the stand-
ard stimulation.
Bias and in particular attrition bias is a serious problem
that could affect the results of the trial. In our trial attri-
tion bias will be handled by describing all patients that
have dropped out of the trial before its completion and
the reasons for dropping out/trial exit will be documented
and provided in a flowchart in a separate manuscript with
the results of this trial. The flowchart will adhere to the
requirements of the CONSORT statement for transparent
reporting of trials. Furthermore, data will be analysed
using linear mixed models. Hence we can use all of the
data, i.e., if a score is missing, it has no effect on other
scores from that same patient.
With the results obtained from this study, that focuses
solely on patients with CRPS, we aim to increase know-
ledge on the effects of SCS in this patient group. However,
caution is advised when extrapolating these results to
other neuropathic pain states because of the single-disease
inclusion approach.
Patient recruitment and inclusion started in August
2011 and the trial is currently ongoing. Completion of the
first part of the study (T0, T1 and crossover) is expected
in early 2015. The completion of T2 and long-term data
collection is expected towards the end of 2015.
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